Clinical Trial Update: Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients [Phase 1]

View source ↗

Summary

Phase I dose-escalation study of SAR125844 in Asian patients with solid tumors has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Neoplasms
• Solid Tumors

Drugs mentioned

• SAR125844 (SAR125844)

Snippet

Sponsor: Sanofi | Conditions: Neoplasm Malignant | Phase 1 | Status: COMPLETED